Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782415 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2783090 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3792251 | 0.91 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1367614 | 0.91 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6560336 | 0.77 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| Phosphoric Acid SCHEMBL5312301 | 0.77 | FAAH (0.53) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7865628 | 0.74 | FAAH (0.43) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL15323484 | 0.74 | FDPS (0.56) | SMPD1FDPSLAP3LPAR1LPAR3 | |
| SCHEMBL16493550 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14629803 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4305 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746913-A1 | LIPID NANOPARTICLES COMPRISING POLYMER-CONJUGATED LIPIDS AND USES THEREOF | Pfizer Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-05-26 | — | — | US | claimed |
| WO-2026090423-A1 | UNIVERSAL LNP COMPOSITIONS | PRIME MEDICINE, INC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | claimed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4720051-A1 | IONIZABLE LIPIDS | Bristol-Myers Squibb Company (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4714454-A2 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics Inc. (CA) | 2026-03-25 | — | — | EP | claimed |
| EP-4709351-A1 | NANOPARTICLES FOR TRANSPORTING ACTIVE SUBSTANCES COMPRISING ANIONIC GROUPS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | Friedrich-Schiller-Universität Jena (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-2006074546-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-07-20 | — | — | WO | claimed |
| US-20060134189-A1 | siRNA silencing of apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2006-06-22 | — | — | US | claimed |
| WO-2006053430-A1 | SIRNA SILENCING OF APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-05-26 | — | — | WO | claimed |
| US-20060083780-A1 | Cationic lipids and methods of use | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-04-20 | — | — | US | claimed |
| US-20060051405-A1 | Compositions for the delivery of therapeutic agents and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-03-09 | — | — | US | claimed |
| US-20060025366-A1 | Immunostimulatory siRNA molecules and uses therefor | PROTIVA BIOTHERAPEUTICS, INC. (GB) | 2006-02-02 | — | — | US | claimed |
| US-20060008910-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTIES, INC. (CA) | 2006-01-12 | — | — | US | claimed |
| WO-2006002538-A1 | IMMUNOSTIMULATORY SIRNA MOLECULES AND USES THEREFOR | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-12 | — | — | WO | claimed |
| WO-2005121348-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |
| WO-2005120152-A2 | CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |